BusinessWorld Online reports that trial results from Eli Lilly showed weight loss it calls record breaking. Tap through for the drug and the numbers.
Recap by typeshit. Full story at BusinessWorld Online.
Weight loss may explain much of the knee benefit, but lab work hints at anti-inflammatory and cartilage effects worth a closer read.
A new GLP-1 described as stronger than current options is being tested in trials, and researchers lay out what people should understand about it.
A SURPASS-4 analysis at ASN Kidney Week 2026 found rapid kidney decline in 5% on tirzepatide versus 13% on insulin glargine, with the biggest gains in high protein groups.
Among 208,970 matched adults with type 2 diabetes, GLP-1 starters had 0.15% new diagnoses versus 0.10% on DPP-4 drugs. Authors call it a signal needing confirmation.
Polskie Radio covers the approval of Novo Nordisk's Wegovy in China. The link carries no further detail on timing or terms.
A piece argues drugs such as Ozempic are driving a health problem that gets little attention. Details beyond the title are thin.
Loading…